Zydus receives final approval to market Pemetrexed for Injection 2

Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection Ahmedabad, India, 26 May, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22). The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapie s. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life -sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com. ***

The release as fetched from its publisher. zyduslife.com ↗